GlobeImmune partners with Gilead Sciences to develop and commercialize HBV vaccines for use in conjunction with oral suppressive antiviral therapies

GlobeImmune Inc.

U.S. / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Gilead Sciences Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

$32,141.2m on 10/28/2011 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Terminated

Sample

01/01/2009

announced

01/01/2009

Terminated